Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 0.64 |
| ▸ | RAB9A | P51151 | 8/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.64 |
| ▸ | RELA | Q04206 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | WNT3A | P56704 | 2/20 | 0.57 |
| ▸ | NCF1 | P14598 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28224829 | 0.87 | NPC1 (0.69) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL11716643 | 0.85 | NPC1 (0.66) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL2638111 | 0.85 | NPC1 (0.66) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL11716649 | 0.85 | NPC1 (0.66) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL10444693 | 0.84 | NPC1 (0.56) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL10605304 | 0.83 | NPC1 (0.64) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL6030882 | 0.83 | NPC1 (0.64) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL2638108 | 0.83 | NPC1 (0.64) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL18248612 | 0.82 | RAB9A (0.63) | NPC1RAB9ANFKB1NFKB2RELA | |
| SCHEMBL14580724 | 0.82 | NPC1 (0.71) | NPC1RAB9ANFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115128-A1 | SELECTIVE PROTEIN LABELING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (IL) | 2012-05-10 | — | — | US | disclosed |
| US-20120115128-A1 | SELECTIVE PROTEIN LABELING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (IL) | 2012-05-10 | — | — | US | disclosed |
| WO-2010129929-A1 | SELECTIVE PROTEIN LABELING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-11-11 | — | — | WO | disclosed |
| US-7605215-B2 | Process for producing olefin copolymerization catalyst and process for producing olefin copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| US-20090192138-A1 | COMPOUNDS | BAESCHLIN DANIEL KASPAR | 2009-07-30 | — | — | US | disclosed |
| US-20080227937-A1 | Process for Producing Olefin Copolymerization Catalyst and Process for Producing Olefin Copolymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-09-18 | — | — | US | disclosed |
| WO-2007071738-A1 | CONDENSED HETEROCYCLIC COMPOUNDS USEFUL AS DPP-IV INHIBITORS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192138-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | NPC1 728/4885RAB9A 3148/4885NFKB1 3665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.